Article ID Journal Published Year Pages File Type
2895147 Atherosclerosis 2006 7 Pages PDF
Abstract

Annexin II (ANXII) is a receptor for tissue plasminogen activator and plasminogen for the conversion to plasmin, which, in turn, induces metalloproteinase-9 (MMP-9). 17β-Estradiol (E2) is reported to decrease plasminogen activity inhibitor-1 and increase plasmin and matrix metalloproteinase activity. However, the combined effects of estrogen and statins on macrophage MMP-9 activity and ANXII expression remain unclear. Treatment of J774A.1 macrophages with 1.0–100 nM of E2 for 24 h increased both MMP-9 activity and ANXII expression in a dose-dependent manner (p < 0.05). Preincubation with EGTA (10 mM) released ANXII from the cell membrane and inhibited the E2-mediated MMP-9 activity as did incubation of macrophages with anti-annexin IgG. In the presence or absence of E2 (5 nM), simvastatin treatment in the range of 0.1–5.0 μM significantly reduced macrophage MMP-9 enzymatic activity (p < 0.005) in a dose-dependent manner. In the presence or absence of E2, simvastatin also decreased ANXII expression (p < 0.05). These findings indicate that ANXII plays a central role in modulating the enzymatic activity of MMP-9 in response to E2 and that E2-mediated ANXII expression and MMP-9 activity can be prevented by simvastatin. Prevention of E2-mediated activation of MMP-9 by simvastatin suggests that concurrent statin use may account for early event risk of myocardial infarction seen with hormone therapy in recent clinical trials.

Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Authors
, , , , ,